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Microfluidic Organ Chip culture devices
are emerging alternatives to conventional
in vitro and animal models due to their
ability to replicate many structural and
functional features of human physiology
and disease states.
Recent innovations demonstrate that
Organ Chip technology is a promising
strategy for virology studies where there
have been successes in reproducingWhile conventional in vitro culture systems and animal models have been used
to study the pathogenesis of viral infections and to facilitate development of
vaccines and therapeutics for viral diseases, models that can accurately reca-
pitulate human responses to infection are still lacking. Human organ-on-a-chip
(Organ Chip) microfluidic culture devices that recapitulate tissue–tissue inter-
faces, fluid flows, mechanical cues, and organ-level physiology have been de-
veloped to narrow the gap between in vitro experimental models and human
pathophysiology. Here, we describe how recent developments in Organ
Chips have enabled re-creation of complex pathophysiological features of
human viral infections in vitro.various viral disease phenotypes.
Organ Chips have enabled investigation
of many aspects of viral infection, includ-
ing virus–host interactions, viral therapy-
resistance evolution, and development
of new antiviral therapeutics, as well as
underlying pathogenesis.
As Organ Chip-based assays provide
accessibility to study virus-induced dis-
eases in real time and at high resolution,
they can open new avenues to uncover
viral pathogenesis in a human-relevant
environment and may eventually enable
development of novel therapeutics and
vaccines.
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Organ Chips are engineered microfluidic devices which, when populated with human cells, offer
the possibility to replicate the complex structures and physiological functions of major functional
units of human organs, both alone and when coupled together fluidically to create human body-
on-chips systems [1,2]. They may complement, or even represent alternatives to, some animal
models and conventional 2D and 3D culture systems by providing greater physiological relevance
and mimicry of human organ-specific responses [3–5]. It has been postulated that Organ Chip
technology could help to reduce the high failure rate in current drug development pipelines
where many drugs that are found to be safe and effective in laboratory animals fail when they
enter human clinical trials [6,7]. As described by Eroom’s law, the number of new drugs approved
per billion US dollars spent on R&D has halved roughly every 9 years since 1950. Thus, successful
Organ Chips could help to reverse the increasing cost of drug development.
Since 2010, when the first physiological relevant Organ Chip model of the lung alveolus was
reported [1,2], numerous other Organ Chips have been developed and applied to study disease
biology and drug analysis. These Organ Chips minimally include one tissue type and generally
feature an interface with an extracellular matrix (ECM) and a neighboring vascular and/or connective
tissue [2,8–10]. There are many chip designs available, both commercially and as prototypes from
academic institutions, which allow various readouts of cell-, tissue-, and organ-level behaviors.
These range from in situ imaging (i.e., optical or mass spectrometric) to built-in electrodes for quan-
tification of transepithelial electrical resistance (TEER) and integrated pH and O2 sensors to sampling
liquid flowing through the channels of the devices [11–14]. Recent advances in nano- and micro-
technology have extended the types of sensors available for in-chip biological processes in so-
called lab-on-chips [15–19]. Chip-based disease models are thus becoming important research
tools in numerous applications [10,20]. Examples include, but are not limited to, diabetic nephropa-
thy and drug toxicities in a kidney glomerulus chip [21,22], intravascular thrombosis in a lung alveolus
chip [23], Alzheimer's disease in a brain chip [24], and radiation and drug toxicities, as well as
modeling a rare genetic disease in a bone marrow chip [25]. As these disease and toxicity models
emerge, new opportunities for drug development are created that may contribute to reducing the
number of failed clinical trials. Several Organ Chips have been developed that model drug pharma-
cokinetics and pharmacodynamics across tissues, yet their predictive values largely remain to be934 Trends in Microbiology, November 2020, Vol. 28, No. 11 https://doi.org/10.1016/j.tim.2020.06.005
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Trends in Microbiologyvalidated with clinical data. However, in one recent study, fluidically coupled human Organ Chips
have been used to qualitatively predict the drug pharmacokinetic responses in patients [26,27].
Tomimic host–microbe interactions specifically, several OrganChip platforms have been developed
that allow study of both pathogenic and nonpathogenic bacteria, and most recently, viral infections.
Among the possibilities being explored are the use of Organ Chip to study infection kinetics, virus–
host interactions, viral pathogenesis and evolution, drug responses, and the development of resis-
tance to drugs and vaccines. Here, we provide an overview of Organ Chip technologies described
for virology application to date andwe discuss opportunities and challenges that lie ahead (Figure 1).
Modeling Viral Diseases in Organ Chips
Liver Chip
In vitro liver models are widely used in hepatology and drug development since they provide a
reasonable mimic of defective liver function and drug metabolization in vivo [28]. A reliable
in vitro liver model relies on reproducing the key elements of the biological processes and the
physiological environment of the liver [29]. Recently, primary human liver cells, which rapidly
lose function in standard culture, have been incorporated into liver chip models to study liver
diseases, such as fatty liver [30], metabolic dysfunction [31], and viral hepatitis [32]. In contrast
to conventional in vitro liver models, typical liver chips can include controlled ratios of various
liver cell types in the correct anatomical orientation and they show improved liver-specific func-
tionality when compared to other in vitro models. These microfluidic liver chips show stableOrgan-on-a-chip
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Figure 1. Application of Organ Chips to Virology. Organ Chips are emerging as a platform for viral disease models. It is
expected that they could uncover signatures in virus evolution and transmission and provide opportunities for personalized
response analysis and novel therapeutic drug development. This is difficult in conventional models or heterogeneous
patient populations.
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and sodium taurocholate cotransporting polypeptide (NTCP), and also recapitulation of the liver
microarchitecture as shown by the presence of hepatic microvilli, tight junctions and functional
bile canaliculi. In contrast to other 3D models and spheroids, where limited diffusion of nutrients
and oxygen leads to necrotic regions, liver chips show overall improved diffusion and transport
properties [29].
Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV) that
is considered as a major global health problem [33]. HBV is responsible for the most common
form of chronic liver infection which may lead to liver fibrosis, cirrhosis, and hepatocellular carci-
noma [34]. The inability to reproduce the complexity of the liver environment using conventional
in vitro models – that usually include only primary human hepatocytes (PHHs) – limits the ability
to study host–pathogen interactions of such diseases [28,35]. In addition, most animal models
are not susceptible to HBV infection or cannot be infected by HBV directly due to its narrow
host range [35,36]. However, liver chip platforms have provided new opportunities to study
viral hepatitis in a more physiological environment. Even using animal liver cells, valuable data
have been obtained on viral infection. A rat liver sinusoid chip system, for example, was applied
for the first time in 2015 to study HBV replication [37]. In this system, primary rat hepatocytes
(PRHs) and immortalized bovine aortic endothelial cells (BAECs) were cocultured on opposite
sides of a microporous membrane in a dual microchannel with continuous perfusion of culture
medium. Hepatocytes maintained differentiation status, normal polygonal morphology,
hepatocyte-specific function, and the expression of PRH-specific markers (ALB, TFN, HNF-4α,
and β-actin) for more than 20 days. PRHs were then successfully infected with recombinant ad-
enoviruses incorporating the HBV genome. This model was subsequently used to develop a
human source model incorporating PHHs [35]. The PHHs retained morphology and viability for
26 days, and expression of the hepatitis B core antigen (HBcAg), and cell secretion of HBV
DNA was detected after direct HBV infection.
Later, another human liver model that allowed microfluidic recirculation of nutrients and
oxygen through the culture medium was used for the study of HBV (Figure 2). In this platform,
PHHs were either seeded alone or in combination with Kupffer cells, the resident macro-
phages in the liver, on collagen-coated polystyrene scaffolds. These liver cultures mimicked
the hepatic sinusoid microarchitecture and were functionally stable for up to 40 days, as
shown by high albumin expression [32]. This chip model is more susceptible to cell culture-
and patient-derived HBV isolates at lower multiplicities of infection (MOI) compared to 2D
cultures and liver spheroids. Also, the levels of albumin secretion and activity of Cyp450,
phase I, II, and III enzymes were superior to those in other tested liver models. Since hallmarks
of host response observed in HBV infection patients were also accurately recapitulated with
elevated levels of IL-8, MIP-3α, SerpinE1, and MCP-1, this model can be applied to study
host–pathogen interactions and identify biomarkers. Other nonparenchymal cells, such as
Kupffer cells, can be added to these cultures to study the contribution of particular liver-
resident cell types to antiviral responses against HBV [38]. The continued development of
such novel platforms, where a more complex liver microenvironment and architecture can
be better mimicked by coculturing different hepatic parenchymal and nonparenchymal cells,
is critical to facilitate the study of HBV liver pathogenesis, immune evasion mechanisms,
and drug-testing studies in the future.
Gut Chip
The human gastrointestinal (GI) tract is structurally complex and dynamic, thus its in vitro simula-




Figure 2. Human Liver Sinusoid Chip for HBV Infection Analysis. (A) Schematic of the human liver sinusoid model, in which the medium is recirculated via a
pneumatically driven micro-pump and the collagen-coated scaffold ensures cell adherence. (B,C) The 3D chip model produces higher levels of albumin and Cyp450
compared to 2D culture models. (D) Chip models can be infected with patient-derived HBV. Adapted from [32] with permission. Abbreviations: DAPI, 4′,6-diamidino-2-
phenylindole dihydrochloride; HBV, hepatitis B virus; PHH, primary human hepatocyte.
Trends in Microbiologybecause the inoculated virus bypasses the native initial infection site in human gastrointestinal epithe-
lium and the absence of some virus-associated receptors for infection of polarized epithelial cells
[39,40]. However, models of small-intestine [41] and large-intestine [42,43] on chips have been suc-
cessful in studying associated physiological and pathological processes (i.e., metabolism, cancer,
host–microbiome interactions, and infection). GI infections are typically caused by bacterial, para-
sitic, or viral infections that lead to gastroenteritis and inflammation, which can involve the stomach,
small intestine, and/or large intestine. To study such infections, a human gut chip was established
[39] which provides a functionally unique platform for the study of enteric virus infection and patho-
genesis that is impossible with conventional culture systems [39,44,45].
Microfluidic human gut chip models generally contain epithelium-lined intestinal lumen in one
channel and a parallel lower ‘vascular’ channel, separated by a porous matrix-coated mem-
brane that supports highly differentiated human villus intestinal epithelium under continuous
perfusion and cyclic mechanical strain which is necessary to mimic the physical microenviron-
ment of human intestine, physiological fluid flow, and peristaltic motion [39]. Undulating villus-
like structures spontaneously form in these chips, which display a tight epithelial barrier and villi
containing microvilli along their apical surfaces. Coxsackievirus B serotype 1 (CVB1) caused
disruption of the villi and integrity of the entire epithelium and passed through the intestinal
lumen into the vascular channel. Additionally, active replication and apical release of newly
formed infectious virions were found along with detectable cytopathic effects (CPEs) and
inflammatory cytokines (IP-10, IL-8) production. This confirmed the ability to mimic secondary
infections and disease propagation in vitro. This type of model has potential for studying a
broad range of enteroviruses. Using state-of-the-art microfluidics technology, engineering
models that recreate more realistic and complex host–pathogen interaction for human enteric
infection will support further understanding of gut-related infections, as well as the develop-
ment of vaccines and therapeutics.Trends in Microbiology, November 2020, Vol. 28, No. 11 937
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The nervous system is the most complex system in the human body. It is composed of a collec-
tion of different types of nerves and neurons, extensive vasculature and somatic structural sup-
port. Our current understanding of human neurobiology and neurological disease is based
mainly on animal models, but because of evolutionary diversity, many cannot faithfully replicate
neuron development and disease progression in humans [46]. Furthermore, most in vitro studies
of neurologic diseases lack cell–cell contact and interstitial fluid flow, which can affect communi-
cation between nonsynaptic neurons [47]. Recent innovations in chip-based technologies have
made it possible to control neuronal connectivity in vitro for deciphering pathological and physio-
logical processes in neuronal networks [48]. Whilst these models will not replace animal models,
for example, for behavioral or cognitive studies, they can be useful for examining underlying
mechanisms of disease. One widely used chip model is a 3D printed nervous system-on-a-
chip that is capable of exhibiting the complexity of some neurological systems and disorders [49].
The device is composed of 3D silicone microchannels printed in parallel on plastic 35 mm dishes
for axonal alignment, with a substrate-chamber sealant layer, to prevent fluid exchange, and three
individual compartmented chambers on top for isolation and spatial organization of neurons and
glial cells (Figure 3). This creates a separate fluid environment for neuronal axons and the soma.
Therefore, virus can be loaded either to the compartment containing neuronal cell bodies or distal
axons [49]. Central nervous system (CNS) neurons, peripheral nervous system (PNS) neurons,
and Schwann cells can then be loaded to establish effective biomimicry of the nervous system,
creating highly alignedCNS–PNS junction networks with associated Schwann cells. After infusion
of the middle chamber containing PNS neurons with pseudorabies virus (PRV), direct infection of
PNS neurons, virus replication, and axon-to-cell spread of viral particles to CNS neurons and
Schwann cells were observed. However, CNS neurons and Schwann cells appeared refractory
to infection, suggesting that there was a bottleneck in virus transmission. This work demon-
strated that 3D printing provides one possible solution for the development of a customizable
nervous system chip. Further biological relevance can be achieved if mechanical and ECM
composition of neural tissues and tissue architectures of brain organization can be matched or
reflected [50].
Kidney Chips
The kidney is a complex and specialized structure containing multiple cell types. This is a major
hurdle in its in vitro modeling. Conventional in vitro kidney models with primary cells have limited
growth capacity and, just like liver, tend to lose their phenotype over time [51]. While kidney
organoids cultured from human induced pluripotent stem cells (hiPSCs) can contain cell types
from different nephron segments, they do not accurately reflect the kidney in vivo, in part due
to the lack of fluid flow and the correct kidney vasculature [52]. However, advances in kidney
chip models are providing new options that overcome many of these hurdles and more closely
resemble the physiological environment and anatomy of the human kidney.
A kidney model recently described is composed of a microfluidic channel, a porous membrane,
and a static liquid well from top to bottom. It was developed to replicate the microenvironment of
distal renal tubules [53]. Distal renal epithelial cells from Madin Darby canine kidney (MDCK) cells
were grown on the porous membrane such that there was transcellular transport into the static
well, providing an interstitial fluid environment. After 3 days of culture, a confluent monolayer
with reabsorption barrier function of the distal renal tubule was formed; continuous injection of
culture medium was then applied to imitate the shear force caused by flow of pro-urine along
the renal tubules, as occurs in vivo. This model was used to study the pathogenesis of PRV-






Figure 3. 3D Printed Nervous System on a Chip for Pseudorabies Virus (PRV) Infection and Transmission.
(A) Fabrication of the 3D printed model nervous system on a chip. (B) Schematic of central nervous system (CNS), showing
CNS neuronal component in chamber 1, peripheral nervous system (PNS) neuronal component in chamber 2, and
peripheral nerve component containing axons and Schwann cells in chamber 3. Direct infection of PNS neurons by PRV led
to replication as indicated by fluorescence micrograph of immature (red capsid) and mature virus particles (yellow puncta) in
the nucleus and axons (C), and spread of viral particles to the CNS neurons and Schwann cells (D). However, CNS neurons
(D-1) and Schwann cells (D-3) exhibited only single primary colors, and not a multicolor profile in PNS neurons (D-2),
suggesting a bottleneck in virus transmission. Adapted from [49] with permission from The Royal Society of Chemistry.
Trends in Microbiologywas described as broken, apical microvilli intertwined on the apical membrane and the expression
levels of Na+ transporters (Na+-Cl− cotransporter and Na+,K+-ATPase) altered. As a result,
decreased Na+ reabsorption was observed, which indicates renal abnormalities in electrolyte regu-
lation. While this model proved successful in demonstrating virus-related pathogenesis and symp-
toms, further developments are still needed to better reflect in vivo physiological and functional
changes in response to infection. Namely, the incorporation of spatial features of kidney, ECM com-
ponents, heterogeneous composition of (human) cell types and fluid shear stress, as well as the
coordination of microvilli, cilia, and glycocalyx with each other in response to flow [52].
Lung Chips
Current lung chip models are capable of mimicking the complex microenvironment and function
of the lung, including alveolus, alveolar–capillary interface, and small airways [54–58]. They offer
novel avenues for studying respiratory diseases, for example, intravascular thrombosis,Trends in Microbiology, November 2020, Vol. 28, No. 11 939
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[23,56,59,60]. Influenza is a viral infection that attacks the respiratory system. The development
of an efficacious antiviral drug against influenza virus is still regarded as a major challenge
[61,62]. This is mainly due to the rapid and continuous influenza virus evolution which leads to
the emergence of mutated viruses, making it resistant to existing therapies and drugs [63–65]. Al-
though influenza virus evolution can be investigated in traditional influenza models (e.g., cell lines,
chicken eggs, and animals), it has long been known that nonhuman models can introduce false
adaption mutations, which has raised a major stumbling block to influenza research in the
wider medical community [66–68].
To address this challenge, a human lung airway chip was used to model influenza virus evolution
and investigate possible therapeutics (Figure 4) [56,69]. The device contains an ‘airway’ channel
in which primary human lung airway epithelial cells (HLAECs) are grown at an air–liquid interface
and human pulmonary microvascular endothelial cells (HPMVECs) are cultured on the ‘vascular’
channel side in the presence of continuous medium flow to mimic vascular perfusion. Mimicking
in vivo morphology, HLAECs differentiated into a mucociliary pseudostratified epithelium and
endothelium forming a planar cell monolayer, which resulted in the development of barrier func-
tion and mucus secretion. Serine proteases necessary for the activation and propagation of
influenza viruses in vivo were also detected. When influenza viruses were inoculated through
the airway channel to mimic in vivo airborne influenza infection, epithelium and endothelium
dysfunction occurred and there was a loss of apical cilia, barrier function disruption, and cytokine
production. The virulence of different influenza virus strains (H1N1, H3N2, H5N1) could also be
recapitulated on these airway chips. In addition, host immune cell recruitment and migration,
responding to infection by influenza virus, and viral clearance by immune cells, were reproduced
in this device. With this advanced model, patient-to-patient transmission was mimicked by pas-
saging virus from chip to chip to predict influenza virus evolution by mutation under the selection
pressure of antiviral drugs (amantadine and oseltamivir). In addition, the device could also support
influenza virus evolution through gene reassortment as occurs when different virus strains
coinfect the same host by coinfecting with H3N2 and H1N1. Moreover, it provides an alternative
preclinical tool for evaluation of new anti-influenza therapeutics (e.g., nafamostat, a serine
protease inhibitor).
To confront the current COVID19 pandemic challenge, the lung airway chip platform was quickly
leveraged to repurpose FDA-approved drugs as potential therapeutics against SARS-CoV-2. To
mimic human infection by airborne SARS-CoV-2, SARS-CoV-2 pseudoparticles (CoV-2pp)
carrying the SARS-CoV-2 spike protein (a key entry factor) were introduced into the air channel
and were thus exposed to the human lung epithelial cells that express high levels of ACE2 and
TMPRSS2 [70,71]. With this platform, amodiaquine and toremifene were identified as potential
entry inhibitors of SARS-CoV-2. This work suggests that the human lung airway chip could be
a particularly useful tool to expedite drug repurposing for pandemic virus-caused crisis
situations.
This airway chip platform has also been adapted for the study of virus-induced asthma exacerba-
tion [72]. The migration of immune cells and the production of virus-induced inflammatory infil-
trates observed in asthma exacerbations in vivo, were reproduced. Infection of the chip with
human rhinovirus 16 (HRV16), commonly associated with asthma exacerbation, was showcased
by replicating the timeframe of virion release and the hallmarks of the cytopathology observed
in humans. Asthma exacerbation was induced by combining IL-13 with HRV16, and the effect
of IL-13 on HRV16-induced inflammatory response was confirmed by the altered release of
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Figure 4. Human Lung Airway Chip Enables Study of Influenza Virus Drug-resistance Evolution. (A) Schematic diagram of a cross-section through the human
airway chip. (B) Schematic diagram of the method used to generate and identify drug-resistant virus strains by human chip-to-chip transmission under drug pressure.
(C) Titers of progeny viruses at the first and eighth passage (P) in control versus amantadine-treated chips. (D) Sequencing graphs showing three mutants (M2-S31N,
M2-S31N/G34E, and M2-S31N/L46P) detected in the amantadine-resistant virus pool. Adapted from [69] with permission from the authors.
Trends in Microbiologyin significantly increased adhesion and transendothelial migration of neutrophils under physiological
flow and shear stress – while MK-7123, a CXCR2 antagonist, reduced neutrophil adhesion and
velocity in all conditions.
Another prevailing lung chip-based approach was used to investigate the complex crosstalk
of coinfection with Staphylococcus aureus and influenza virus [73]. Alveolar epithelial cells (NCI-Trends in Microbiology, November 2020, Vol. 28, No. 11 941
Trends in MicrobiologyH441 cells) and monocyte-derived macrophages were cocultured within the upper chamber of
the chip interfacing an air phase, while human umbilical vein endothelial cells (HUVECs) were cul-
tured within the lower chamber, perfused with culture medium. A stable air–liquid interface and
biological barrier, a morphological feature of the lung, were formed after 14 days of cultivation.
The model was then coinfected with S. aureus and influenza virus to investigate host–pathogen
interaction in an immune environment by integrating macrophages and monitoring the resultant
immune response. This study demonstrated that coinfection led to overall higher expression of
cytokines and chemokines (IL-1β, IL-6, MCP-1, and IFN-γ) when compared to single infection.
Moreover, endothelial impairment and subsequent vascular leakage upon coinfection were also
demonstrated, which is a hallmark of acute lung injury.
Despite the indisputable utility of these in vitro models, which utilize lung-related epithelial and
endothelial cells, models incorporating various cell types and tissue components that represent
the vascular, muscular, and immune systems, as well as cartilage of human lung, are still lacking.
Therefore, further innovations to develop more complex systems capable of simulating a more
realistic host–pathogen interaction in vitro are needed for the development of therapeutic and
vaccination solutions for respiratory disease.
Modeling Viral Hemorrhagic Syndrome On-Chip
Impairment of vascular integrity is a hallmark of a number of viral infections in humans, in par-
ticular, viral hemorrhagic syndromes (VHSs) caused by viruses such as Ebola (EBOV) and
Lassa (LASV) [74,75]. The integrity impairment is caused directly via infection or indirectly via
interactions between vessels and circulating viral materials [76,77]. Nonhuman primate (NHP)
models are used to uncover the pathophysiology associated with VHS and develop corre-
sponding vaccinations and therapeutics [78]. However, NHP models have several limitations.
In particular, the need for host-adapted viruses and BSL-4 facilities which are inherently time
consuming and extremely costly and are associated with ethical issues [79]. Furthermore,
NHP models can also be nonrepresentative of the disease physiology and drug pharmacology
observed in patients [26].
The use of Organ Chips in investigating VHS has recently been explored and its applicability to
disease modeling and drug analysis has been demonstrated. A high-throughput chip-based
model for EBOV-induced vascular integrity loss was developed using phase-guide-based
technology (Figure 5) [80]. A phase-guide design allows interfacing of two parallel channels without
any physical wall in between, while maintaining the ability to grow tissues or form ECM without
mixing the channels’ contents. To generate a high-throughput VHSmodel, a total of 96 perfusable
and endothelialized microvessels within a fabricated phase-guide channel system was cultured
with HUVECs at the interface of a collagen type I network and subjected to continuous perfusion.
Vascular barrier function was demonstrated, as was sensitivity to physiological vasoactive com-
pounds such as histamine. Luminal infusion of Ebola virus-like particles (VLPs) led to a dramatic
increase in vascular permeability and clear increases in actin stress fiber formation.
This platform proved promising in the assessment of disease severity. In agreement with clinical
findings [74,81], the in vitro analysis showed a clear correlation between the integrity loss and viral
load as well as the concentration of circulating Ebola glycoprotein (GP1,2), a key mediator of
vascular cell injury. These results indicated that both VLP- and GP1,2-induced vascular impair-
ment can be detected in this chip model. Furthermore, the study demonstrated activation of
the Rho/ROCK pathway as necessary and sufficient to produce VHS on the chip. Activation of
the Rho/ROCK pathway was seen upon infusion of the VLPs or the purified GP1,2, leading to
changes in the actin network and the mechanical tension applied to endothelial cell junctions.942 Trends in Microbiology, November 2020, Vol. 28, No. 11
Outstanding Questions
Can hiPSC technology be used to
develop individualized Organ Chips
with homogeneous genotype and
phenotypes to help overcome
interindividual variabilities in viral
disease progression and facilitate
personalized antiviral drug development?
Is it possible to integrate the regulatory
effect of both the endocrine and
nervous systems on Organ Chips for
investigating virus-induced infection?
Is it possible to interconnect multiple
organs-on-chips to produce human
body-on-chips models that provide
new insights into viral pathogenesis at
a complex and systemic human level?
Can complex immune processes be
integrated into Organ Chips to simulate
virus-related inflammatory responses,
to improve the pathophysiological rele-
vance of the models?
Are the Organ Chip models currently
available sufficiently equipped for
studying newly emerging viruses in
the future?
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Figure 5. Viral Hemorrhagic Syndrome (VHS) Modeled On-chip to Study Ebola Virus (EBOV)-induced Loss of
Vascular Integrity and Efficacy of Drugs. (A) Aminimal design for Ebola VHS-on-a-chip. (B) Endothelial processes involved
in VHS. (C) Apparent permeability (Papp) of microvessels in response to Ebola virus-like particles (VLPs). Microvessels were
treated for 2 h with the indicated concentrations of VLPs, followed by a permeability assay. (D) Dose response to a drug
candidate (melatonin) in microvessels exposed to 1 μg/ml Ebola VLPs for 2 h, followed by a permeability assay.
Abbreviations: ECM, extracellular matrix; HUVECs, human umbilical vein endothelial cells. Adapted from [80] with permission.
Trends in MicrobiologyThis raised the question as to whether inhibitors of this pathway, or targeting this mechanical
mechanism, can be considered as therapeutic options. As proof-of-concept, the efficacy of
two candidate drugs, FX06 [82–84] and melatonin [85–88], to counteract vascular leakage in
VLP-treated vessels was demonstrated; these drugs target the mechanical elements VE-
cadherin and associated actin bundles and the Rho/ROCK signaling pathway, respectively.
This opens new opportunities for developing targeted therapeutics using Organ Chip-based
models.
Concluding Remarks
Multiple studies, as described here, have illustrated how viral diseases can be reproduced using
Organ Chip technology. Microfluidic Organ Chip platforms can provide accessibility to study
virus-induced diseases in (human) organ-relevant settings, in real time and at high resolution,
which cannot be achieved by traditional in vitro systems or animal models. Additionally, the
Organ Chip approach provides flexibility and thus can be adapted to emerging needs, for
example, in the case of the current pandemic of SARS-CoV-2 virus that has infected millionsTrends in Microbiology, November 2020, Vol. 28, No. 11 943
Trends in Microbiologyand killed thousands of people globally [89,90]. Although researchers have recapitulated SARS-
CoV-2 infection in rhesus macaques [91], ferrets [92], and hamsters [93], none of these animal
models faithfully mimics the morbidity or mortality seen in many human patients. Thus, we are
still facing many limitations associated with animal models that may seriously delay or even
cause failure in the development of vaccines and therapies. Organ Chip-based models may
provide opportunities to overcome at least some of these limitations, now or in the future, and
provide a new insight into host response to infection and disease pathogenesis.
Human induced pluripotent stem cells (hiPSCs) and human adult stem cell organoids are now be-
coming a viable alternative for more widely used primary cells and cell lines to model functional
organ or tissue units. In addition, hiPSCs allow many types of cell to be derived from the same
genetic background so that fully personalized Organ Chip models are becoming feasible
[94,95]. Significant interindividual variabilities in disease progression have been reported for
patients with viral infections. Examples include EBOV and LASV with dead/survivor ratios of 2:1
and about 4:1i,ii respectively (similarly for other VHS-causing viruses). What causes this variability
is largely unknown. The use of hiPSCs derived from a single patient could enable modeling of
disease progression and drug efficacy on individuals or groups of patients as well as targeted
drug development [96–98].
Other future possibilities include using 3D printing technology (i.e., customization, rapid prototyping
andmultimaterial processing capabilities) to create more complicated and rapid fabrication of next-
generation Organ Chips. The level of throughput and utility of current Organ Chip analyses is hin-
dered by the commonly used readouts based on high-content microscope images. Combination
with other screening assays (in line with metabolomics and sensors, single-cell sequencing etc.)
may provide solutions. Finally, viruses such as SARS-CoV-2 or Ebola, may affect several organs
in an interconnected manner. Ebola virus, for example, affects vessels directly and indirectly via
liver and immune cells [74,77,85]. SARS-CoV-2 has been shown to be able to replicate in nasal tur-
binate, trachea, lung, kidney, and intestine in ferrets as shown by viral RNA quantification and de-
tection of viral antigens [92]. Hence, recapitulating the crosstalk between multiple organs could be
the focus of future efforts (see Outstanding Questions).
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